

**Reference List 1977-2006****No. 1-264**

- (1) Fischerman K, Mouridsen HT. Danish Breast Cancer Cooperative Group--DBCG. *Ugeskr Laeger* 1977 October 17;139(42):2493-4.
- (2) Brincker H, Mouridsen H, Anersen KW, Andersen J, Castberg T, Fischerman K et al. Increased breast-cancer recurrence rate after adjuvant therapy with levamisole. A preliminary report. Executive Committee of the Danish Breast Cancer Cooperative Group. *Lancet* 1980 October 18;2(8199):824-7.
- (3) Andersen JA, Fischermann K, Hou-Jensen K, Henriksen E, Andersen KW, Johansen H et al. Selection of high risk groups among prognostically favorable patients with breast cancer. *Ann Surg* 1981 July;194(1):1-3.
- (4) Andersen KW, Mouridsen HT, Castberg T, Fischerman K, Andersen J, Hou-Jensen K et al. Organisation of the Danish adjuvant trials in breast cancer. *Dan Med Bull* 1981 August;28(3):102-6.
- (5) Keiding N, Andersen KW, Andersen J, Brincker H, Mouridsen HT. Danish Breast Cancer Cooperative Group. *Experientia Suppl* 1982;41:591-9.
- (6) Rasmussen BB, Hilkens J, Hilgers J, Nielsen HH, Thorpe SM, Rose C. Monoclonal antibodies applied to primary human breast carcinoma: relationship to menopausal status, lymph node status, and steroid hormone receptor content. (A preliminary report ). *Breast Cancer Res Treat* 1982;Volume 2, nr. 4, 1982:401-5.
- (7) Rossing N, Munck O, Nielsen SP, Andersen KW. What do early bone scans tell about breast cancer patients? *Eur J Cancer Clin Oncol* 1982 July;18(7):629-36.
- (8) Brincker H, Mouridsen HT, Andersen KW. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. *Breast Cancer Res Treat* 1983;3(1):91-5.
- (9) Rose C, Thorpe SM, Mouridsen HT, Andersen JA, Brincker H, Andersen KW. Antiestrogen treatment of postmenopausal women with primary high risk breast cancer. *Breast Cancer Res Treat* 1983;3(1):77-84.
- (10) Thorpe SM, Rose C, Pedersen BV, Rasmussen BB. Estrogen and progesterone receptor profile patterns in primary breast cancer. *Breast Cancer Res Treat* 1983;3(1):103-10.
- (11) Andersen JA, Blichert-Toft M, Kjaergaard J, Andersen KW, Mouridsen HT. Prognostic significance of residual cancer tissue after diagnostic biopsy in breast carcinoma. Three-year short-term results. *Eur J Cancer Clin Oncol* 1984 June;20(6):765-70.
- (12) Fischerman K, Mouridsen HT. Danish Breast Cancer Cooperative Group (DBCG). Present status and experience. *Acta Chir Scand Suppl* 1984;519:55-9.
- (13) Mouridsen HT, Rose C, Brincker H, Thorpe SM, Rank F, Fischerman K et al. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. *Recent Results Cancer Res* 1984;96:117-28.
- (14) Thomsen HS, Lund JO, Munck O, Andersen KW, Stockel M, Rossing N. Bone metastases in primary operable breast cancer. The role of serial scintigraphy. *Eur J Cancer Clin Oncol* 1984 August;20(8):1019-23.

- (15) Thomsen HS, Munck O, Andersen KW. [The value of routine bone scintigraphy in primary operable breast cancer]. *Ugeskr Laeger* 1984 June 25;146(26):1915-8.
- (16) Thorpe SM, Olsen K, Pedersen KO, Poulsen HS, Rose C. Quality control of estrogen and progesterone receptor analyses in Denmark. *Recent Results Cancer Res* 1984;91:91-3.
- (17) Kjaergaard J, Blichert-Toft M, Andersen JA, Rank F, Pedersen BV. Probability of false negative nodal staging in conjunction with partial axillary dissection in breast cancer. *Br J Surg* 1985 May;72(5):365-7.
- (18) Rasmussen BB. Human Mucinous Breast Carcinomas and their Lymph Node Metastases. A Histological Review of 247 Cases. *Path Res Pract* 1985;180(4):377-82.
- (19) Rasmussen BB, Pedersen BV, Thorpe SM, Rose C. Elastosis in relation to prognosis in primary breast carcinoma. *Cancer Res* 1985 March;45(3):1428-30.
- (20) Rasmussen BB, Rose C, Thorpe SM, Andersen KW, Hou-Jensen K. Argyrophilic cells in 202 human mucinous breast carcinomas. Relation to histopathologic and clinical factors. *Am J Clin Pathol* 1985 December;84(6):737-40.
- (21) Rasmussen BB, Pedersen BV, Thorpe SM, Hilkens J, Hilgers J, Rose C. Prognostic value of surface antigens in primary human breast carcinomas, detected by monoclonal antibodies. *Cancer Res* 1985 March;45(3):1424-7.
- (22) Rose C, Mouridsen HT, Thorpe SM, Andersen J, Blichert-Toft M, Andersen KW. Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: 72 months of life-table analysis and steroid hormone receptor status. *World J Surg* 1985 October;9(5):765-74.
- (23) Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. *Lancet* 1985 January 5;1(8419):16-9.
- (24) DeSombre ER, Thorpe SM, Rose C, Blough RR, Andersen KW, Rasmussen BB et al. Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. *Cancer Res* 1986 August;46(8 Suppl):4256s-64s.
- (25) Kamby C, Rose C, Iversen H, Holm NV, Andersen KW, Thorpe SM. Pattern of metastases in human breast carcinoma in relation to estrogen receptor status. *Anticancer Res* 1986 January;6(1):107-11.
- (26) Kamby C, Rose C, Iversen H, Holm NV, Andersen KW, Thorpe SM. [The pattern of metastases in breast cancer and the relation to estrogen receptor status]. *Ugeskr Laeger* 1986 September 29;148(40):2546-8.
- (27) Mouridsen HT, Andersen AP, Brincker H, Dombernowsky P, Rose C, Andersen KW. Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: present status of Danish Breast Cancer Cooperative Group trials. *NCI Monogr* 1986;(1):115-8.
- (28) Rose C, Kamby C, Mouridsen HT, Bastholt L, Brincker H, Skovgaard-Poulsen H et al. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. *Breast Cancer Res Treat* 1986;7 Suppl:S45-S50.
- (29) Thorpe SM, Rose C. Oestrogen and progesterone receptor determinations in breast cancer: technology and biology. *Cancer Surv* 1986;5(3):505-25.

- (30) Thorpe SM, Rose C, Rasmussen BB, King WJ, DeSombre ER, Blough RM et al. Steroid hormone receptors as prognostic indicators in primary breast cancer. *Breast Cancer Res Treat* 1986;7 Suppl:S91-S97.
- (31) Brincker H, Rose C, Rank F, Mouridsen HT, Jakobsen A, Dombernowsky P et al. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. *J Clin Oncol* 1987 November;5(11):1771-8.
- (32) Kamby C, Rose C, Ejlersen B, Andersen J, Birkler NE, Rytter L et al. Stage and pattern of metastases in patients with breast cancer. *Eur J Cancer Clin Oncol* 1987 December;23(12):1925-34.
- (33) Keiding N, Bayer T, Watt-Boolsen S. Confirmatory analysis of survival data using left truncation of the life times of primary survivors. *Stat Med* 1987 December;6(8):939-44.
- (34) Rank F, Dombernowsky P, Jespersen NC, Pedersen BV, Keiding N. Histologic malignancy grading of invasive ductal breast carcinoma. A regression analysis of prognostic factors in low-risk carcinomas from a multicenter trial. *Cancer* 1987 September 15;60(6):1299-305.
- (35) Rasmussen BB. Primære mucinøse mammakarcinomer. Histopatologiske, immunhistokemiske og kliniske karakteristika. Københavns Universitet; 1987.
- (36) Rasmussen BB, Rose C, Christensen IB. Prognostic factors in primary mucinous breast carcinoma. *Am J Clin Pathol* 1987 February;87(2):155-60.
- (37) Thomsen HS, Rasmussen D, Munck O, Lund JO, Gerhard-Nielsen V, Terkildsen T et al. Bone metastases in primary operable breast cancer. The role of a yearly scintigraphy. *Eur J Cancer Clin Oncol* 1987 June;23(6):779-81.
- (38) Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T, Keiding N. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. *Cancer Res* 1987 November 15;47(22):6126-33.
- (39) Papers from the Danish Breast Cancer Cooperative Group presented at the ten-year anniversary. Copenhagen, January 22-23, 1988. *Acta Oncol* 1988;27(6A):591-771.
- (40) Andersen J, Poulsen HS. Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases. An immunohistochemical study in human breast cancer. *Acta Oncol* 1988;27(6A):761-5.
- (41) Andersen JA, Nielsen M, Blichert-Toft M. The growth pattern of in situ carcinoma in the female breast. *Acta Oncol* 1988;27(6A):739-43.
- (42) Andersen KW, Mouridsen HT. Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. *Acta Oncol* 1988;27(6A):627-47.
- (43) Axelsson CK, Blichert-Toft M. Low-risk breast cancer patients treated by mastectomy and lower axillary dissection. The present status of the Danish Breast Cancer Cooperative Group Trial 77-A. *Acta Oncol* 1988;27(6A):605-9.
- (44) Blichert-Toft M, Brincker H, Andersen JA, Andersen KW, Axelsson CK, Mouridsen HT et al. A Danish randomized trial comparing breast-preserving therapy with mastectomy in mammary carcinoma. Preliminary results. *Acta Oncol* 1988;27(6A):671-7.

- (45) Blichert-Toft M, Dyreborg U, Andersen J. Diagnostic strategy in the management of patients with breast symptoms. A recommended design and present experience. *Acta Oncol* 1988;27(6A):597-600.
- (46) Brincker H. Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen. *Acta Oncol* 1988;27(6A):729-32.
- (47) Dombernowsky P, Brincker H, Hansen M, Mouridsen HT, Overgaard M, Panduro J et al. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B. *Acta Oncol* 1988;27(6A):691-7.
- (48) Ewertz M, Duffy SW. Risk of breast cancer in relation to reproductive factors in Denmark. *Br J Cancer* 1988 July;58(1):99-104.
- (49) Ewertz M. Risk of breast cancer in relation to social factors in Denmark. *Acta Oncol* 1988;27(6b):787-92.
- (50) Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. *Int J Cancer* 1988 December 15;42(6):832-8.
- (51) Ewertz M. Risk factors for breast cancer and their prognostic significance. *Acta Oncol* 1988;27(6A):733-7.
- (52) Fischerman K, Mouridsen HT. Danish Breast Cancer Cooperative Group (DBCG). Structure and results of the organization. *Acta Oncol* 1988;27(6A):593-6.
- (53) Graversen HP, Blichert-Toft M, Andersen JA, Zedeler K. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. *Eur J Surg Oncol* 1988 October;14(5):407-12.
- (54) Graversen HP, Blichert-Toft M, Dyreborg U, Andersen J. In situ carcinomas of the female breast. Incidence, clinical findings and DBCG proposals for management. *Acta Oncol* 1988;27(6A):679-82.
- (55) Kamby C, Andersen J, Ejlertsen B, Birkler NE, Rytter L, Zedeler K et al. Histological grade and steroid receptor content of primary breast cancer--impact on prognosis and possible modes of action. *Br J Cancer* 1988 October;58(4):480-6.
- (56) Kamby C, Rose C, Ejlertsen B, Andersen J, Birkler NE, Rytter L et al. Adjuvant systemic treatment and the pattern of recurrences in patients with breast cancer. *Eur J Cancer Clin Oncol* 1988 March;24(3):439-47.
- (57) Kamby C, Ejlertsen B, Andersen J, Birkler NE, Rytter L, Zedeler K et al. The pattern of metastases in human breast cancer. Influence of systemic adjuvant therapy and impact on survival. *Acta Oncol* 1988;27(6A):715-9.
- (58) Kiaer H, Andersen JA, Rank F, Pedersen BV. Quality control of patho-anatomical diagnosis of carcinoma of the breast. *Acta Oncol* 1988;27(6A):745-7.
- (59) Krag C. Breast reconstruction after mastectomy. *Acta Oncol* 1988;27(6A):687-90.
- (60) Lober J, Sogaard J, Mouridsen HT, Jorgensen J. Treatment costs of adjuvant cytotoxic therapy in premenopausal breast cancer patients. *Acta Oncol* 1988;27(6A):767-71.

- (61) Lykkesfeldt AE, Balslev I, Christensen IJ, Larsen JK, Molgaard H, Rasmussen BB et al. DNA ploidy and S-phase fraction in primary breast carcinomas in relation to prognostic factors and survival for premenopausal patients at high risk for recurrent disease. *Acta Oncol* 1988;27(6A):749-56.
- (62) Mouridsen HT, Rose C, Overgaard M, Dombernowsky P, Panduro J, Thorpe S et al. Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. *Acta Oncol* 1988;27(6A):699-705.
- (63) Ottesen G, Andersen JA, Blichert-Toft M, Axelsson C. Frequency and types of chest wall recurrences among node negative breast cancer patients. *Acta Oncol* 1988;27(6A):601-4.
- (64) Overgaard M, Christensen JJ, Johansen H, Nybo-Rasmussen A, Brincker H, van der KP et al. Postmastectomy irradiation in high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group trials. *Acta Oncol* 1988;27(6A):707-14.
- (65) Rasmussen BB, Thorpe SM, Norgaard T, Rasmussen J, Agdal N, Rose C. Immunohistochemical steroid receptor detection in frozen breast cancer tissue. A multicenter investigation. *Acta Oncol* 1988;27(6A):757-60.
- (66) Rose C, Mouridsen HT. Endocrine therapy of advanced breast cancer. *Acta Oncol* 1988;27(6A):721-8.
- (67) Rytto N, Holm NV, Qvist N, Blichert-Toft M. Influence of adjuvant irradiation on the development of late arm lymphedema and impaired shoulder mobility after mastectomy for carcinoma of the breast. *Acta Oncol* 1988;27(6A):667-70.
- (68) Thomsen HS, Lund JO, Munck O, Rossing N. The value of pre-scheduled bone scintigraphies in breast cancer. *Acta Oncol* 1988;27(6A):617-9.
- (69) Thorpe SM, Poulsen HS, Pedersen KO, Rose C. Quality control of receptor analyses of breast cancer tissue in Denmark. *Acta Oncol* 1988;27(6A):621-5.
- (70) Thorpe SM. Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance. *Acta Oncol* 1988;27(1):1-19.
- (71) Thorpe SM, Poulsen HS, Pedersen KO, Rose C. Impact of standardization of estrogen and progesterone receptor assays of breast cancer biopsies in Denmark. *Eur J Cancer Clin Oncol* 1988 August;24(8):1263-9.
- (72) Watt-Boolsen S, Dyreborg U, Andersen JA, Blichert-Toft M. Bioptic strategy in breast cancer. *Acta Oncol* 1988;27(6A):683-5.
- (73) Watt-Boolsen S, Jacobsen K, Blichert-Toft M. Total mastectomy with special reference to surgical technique, extent of axillary dissection and complications. *Acta Oncol* 1988;27(6A):663-5.
- (74) Winkel P. The Danish Breast Cancer Group (DBCG) biochemical tumor marker program. *Acta Oncol* 1988;27(6A):611-5.
- (75) Zedeler K. Assessment and presentation of survival experience in the Danish Breast Cancer Cooperative Group. *Acta Oncol* 1988;27(6A):649-62.
- (76) Bastholt L, Dalmark M, Jakobsen A, Gadeberg CC, Sandberg E, Mouridsen HT. Oral idarubicin in the treatment of advanced breast cancer. *Acta Oncol* 1989;28(6):893-7.

- (77) Kamby C, Ejlersten B, Andersen J, Birkler NE, Rytter L, Zedeler K et al. Body size and menopausal status in relation to the pattern of spread in recurrent breast cancer. *Acta Oncol* 1989;28(6):795-9.
- (78) Klein JP, Keiding N, Kamby C. Semiparametric Marshall-Olkin models applied to the occurrence of metastases at multiple sites after breast cancer. *Biometrics* 1989 December;45(4):1073-86.
- (79) Pedersen L, Holck S, Schiodt T, Zedeler K, Mouridsen HT. Inter- and intraobserver variability in the histopathological diagnosis of medullary carcinoma of the breast, and its prognostic implications. *Breast Cancer Res Treat* 1989 October;14(1):91-9.
- (80) Thomsen HS, Lund JO, Munck O, Andersen KW. Experience with 7,604 bone scintigraphies at time of operation for breast cancer 1977-1987. *Dan Med Bull* 1989 October;36(5):481-3.
- (81) Thorpe SM. Estrogen and progesterone receptor determinations in breast cancer: Technology, biology, and clinical significance. København Universitet; 1989.
- (82) Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S et al. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. *Cancer Res* 1989 November 1;49(21):6008-14.
- (83) Vestergaard A, Herrstedt J, Thomsen HS, Dombernowsky P, Zedeler K. The value of yearly chest X-ray in patients with stage I breast cancer. *Eur J Cancer Clin Oncol* 1989 April;25(4):687-9.
- (84) Watt-Boolsen S, Ottesen G, Andersen JA, Bayer T, Jespersen NC, Keiding N et al. Significance of incisional biopsy in breast carcinoma: results from a clinical trial with intended excisional biopsy. *Eur J Surg Oncol* 1989 February;15(1):33-7.
- (85) Andersen J, Thorpe SM, King WJ, Rose C, Christensen I, Rasmussen BB et al. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. *Eur J Cancer* 1990 April;26(4):442-9.
- (86) Bastholt L, Dalmark M, Jakobsen A, Gadeberg CC, Sandberg E, Mouridsen HT. Weekly oral idarubicin in postmenopausal women with advanced breast cancer. A phase II study. *Acta Oncol* 1990;29(2):143-6.
- (87) Ewertz M, Gill C. Dietary factors and breast-cancer risk in Denmark. *Int J Cancer* 1990 November 15;46(5):779-84.
- (88) Ewertz M. Smoking and breast cancer risk in Denmark. *Cancer Causes Control* 1990 July;1(1):31-7.
- (89) Kamby C. The pattern of metastases in human breast cancer: methodological aspects and influence of prognostic factors. *Cancer Treat Rev* 1990 March;17(1):37-61.
- (90) Logager VB, Vestergaard A, Herrstedt J, Thomsen HS, Zedeler K, Dombernowsky P. The limited value of routine chest X-ray in the follow-up of stage II breast cancer. *Eur J Cancer* 1990;26(5):553-5.
- (91) Mondrup K, Olsen NK, Pfeiffer P, Rose C. Clinical and electrodiagnostic findings in breast cancer patients with radiation-induced brachial plexus neuropathy. *Acta Neurol Scand* 1990 February;81(2):153-8.
- (92) Olsen NK, Pfeiffer P, Mondrup K, Rose C. Radiation-induced brachial plexus neuropathy in breast cancer patients. *Acta Oncol* 1990;29(7):885-90.

- (93) Overgaard M, Christensen JJ, Johansen H, Nybo-Rasmussen A, Rose C, van der KP et al. Evaluation of radiotherapy in high-risk breast cancer patients: report from the Danish Breast Cancer Cooperative Group (DBCG 82) Trial. *Int J Radiat Oncol Biol Phys* 1990 November;19(5):1121-4.
- (94) Pedersen L, Schiodt T, Holck S, Zedeler K. The prognostic importance of syncytial growth pattern in medullary carcinoma of the breast. *APMIS* 1990 October;98(10):921-6.
- (95) [A randomized study of tumor resection versus mastectomy in breast cancer. 2. 6-year results of the DBCG-82TM (Danish Breast Cancer Cooperative Group) protocol]. *Ugeskr Laeger* 1991 August 12;153(33):2272-6.
- (96) Andersen J, Thorpe SM, Rose C, Christensen I, Rasmussen BB, Poulsen HS. Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its usefulness compared to dextran-coated charcoal assay. *Acta Oncol* 1991;30(6):685-90.
- (97) Andersson M, Storm HH, Mouridsen HT. Adjuvant chemotherapy and subsequent malignant disease. *Lancet* 1991 October 5;338(8771):885-6.
- (98) Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. *J Natl Cancer Inst* 1991 July 17;83(14):1013-7.
- (99) Axelsson CK, Andersen JA, Andersen KW, Blichert-Toft M, Dombernowsky P, Hansen M et al. [Prognosis after surgical treatment of breast cancer. 3. The low-risk group of the DBCG (Danish Breast Cancer Cooperative Group)]. *Ugeskr Laeger* 1991 August 12;153(33):2276-9.
- (100) Dombernowsky P, Andersen JA, Andersen KW, Axelsson CK, Blichert-Toft M, Hansen M et al. [Adjuvant chemotherapy in premenopausal and menopausal high-risk patients with breast cancer. 4. Results of the DBCG (Danish Breast Cancer Cooperative Group) 77B study]. *Ugeskr Laeger* 1991 August 12;153(33):2280-3.
- (101) Eickhoff JH, Andersen J, Laybourn C. Perioperative blood transfusion does not promote recurrence and death after mastectomy for breast cancer. The Danish Breast Cancer Cooperative Group. *Br J Surg* 1991 November;78(11):1358-61.
- (102) Ewertz M. Alcohol consumption and breast cancer risk in Denmark. *Cancer Causes Control* 1991 July;2(4):247-52.
- (103) Ewertz M, Gillanders S, Meyer L, Zedeler K. Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer. *Int J Cancer* 1991 October 21;49(4):526-30.
- (104) Jakobsen P, Bastholt L, Dalmark M, Pfeiffer P, Petersen D, Gjedde SB et al. A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. *Cancer Chemother Pharmacol* 1991;28(6):465-9.
- (105) Kamby C, Andersen J, Ejlertsen B, Birkler NE, Rytter L, Zedeler K et al. Pattern of spread and progression in relation to the characteristics of the primary tumour in human breast cancer. *Acta Oncol* 1991;30(3):301-8.
- (106) Pedersen L, Zedeler K, Holck S, Schiodt T, Mouridsen HT. Medullary carcinoma of the breast, proposal for a new simplified histopathological definition. Based on prognostic observations and observations on inter- and intraobserver variability of 11 histopathological characteristics in 131 breast carcinomas with medullary features. *Br J Cancer* 1991 April;63(4):591-5.

- (107) Rose C, Andersen JA, Andersen KW, Axelsson CK, Blichert-Toft M, Dombernowsky P et al. [Adjuvant endocrine treatment of postmenopausal patients with breast cancer with high risk of recurrence. 5. Results from the DBCG (Danish Breast Cancer Cooperative Group) 77C randomized trial]. *Ugeskr Laeger* 1991 August 12;153(33):2283-7.
- (108) Thomsen HS, Andersen JA, Andersen KW, Axelsson CK, Blichert-Toft M, Dombernowsky P et al. [Rationalization profits of radiographic diagnosis with systematic follow-up DBCG (Danish Breast Cancer Cooperative Group) programs. 1]. *Ugeskr Laeger* 1991 August 12;153(33):2270-2.
- (109) Andersen J. Determination of estrogen receptors in paraffin-embedded tissue. Techniques and the value in breast cancer treatment. *Acta Oncol* 1992;31(6):611-27.
- (110) Andersen J, Eickhoff JH, Laybourn C. [Perioperative blood transfusion does not increase the risk of recurrence or death after mastectomy in breast cancer]. *Ugeskr Laeger* 1992 March 16;154(12):777-9.
- (111) Andersson M, Storm HH, Mouridsen HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. *Acta Oncol* 1992;31(2):259-63.
- (112) Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). *Eur J Cancer* 1992;28A(8-9):1415-8.
- (113) Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, Andersen KW et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. *J Natl Cancer Inst Monogr* 1992;(11):19-25.
- (114) Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. *Lancet* 1992 January 4;339(8784):1-15.
- (115) Graversen HP, Zedeler K, Andersen JA, Axelsson CK, Blichert-Toft M. [Axillary dissection in primary surgical treatment of breast cancer: risk of false-negative axillary status]. *Ugeskr Laeger* 1992 November 23;154(48):3392-5.
- (116) Kamby C. Metastasemønsteret ved cancer mammae. Metodologiske aspekter og relation til prognostiske faktorer. Københavns Universitet; 1992.
- (117) Mouridsen HT, Andersen J, Andersen KW, Axelsson C, Blichert-Toft M, Dombernowsky P et al. Classical prognostic factors in node-negative breast cancer: the DBCG experience. *J Natl Cancer Inst Monogr* 1992;(11):163-6.
- (118) Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Ductal carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. *Am J Surg Pathol* 1992 December;16(12):1183-96.
- (119) Zedeler K, Keiding N, Kamby C. Differential influence of prognostic factors on the occurrence of metastases at various anatomical sites in human breast cancer. *Stat Med* 1992 February 15;11(3):281-94.
- (120) Andersen J. Determination of estrogen receptors in paraffin-embedded tissue. Techniques and the value in breast cancer treatment. Aarhus Universitet; 1993.
- (121) Christensen L, Schiodt T, Blichert-Toft M. Sarcomatoid tumours of the breast in Denmark from 1977 to 1987. A clinicopathological and immunohistochemical study of 100 cases. *Eur J Cancer* 1993;29A(13):1824-31.



- (122) Ejlertsen B, Pfeiffer P, Pedersen D, Mouridsen HT, Rose C, Overgaard M et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. *Eur J Cancer* 1993;29A(4):527-31.
- (123) Ewertz M. Breast cancer in Denmark. Incidence, risk factors, and characteristics of survival. *Acta Oncol* 1993;32(6):595-615.
- (124) Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. *Cancer Res* 1993 June 1;53(11):2513-21.
- (125) Holck S, Pedersen L, Schiodt T, Zedeler K, Mouridsen H. Vimentin expression in 98 breast cancers with medullary features and its prognostic significance. *Virchows Arch A Pathol Anat Histopathol* 1993;422(6):475-9.
- (126) Ladekarl M, Sorensen FB. Prognostic, quantitative histopathologic variables in lobular carcinoma of the breast. *Cancer* 1993 November 1;72(9):2602-11.
- (127) Ladekarl M, Sorensen FB. Quantitative histopathological variables in in situ and invasive ductal and lobular carcinomas of the breast. *APMIS* 1993 December;101(12):895-903.
- (128) Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. *Am J Surg Pathol* 1993 January;17(1):14-21.
- (129) Thorpe SM, Christensen IJ, Rasmussen BB, Rose C. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. *Eur J Cancer* 1993;29A(7):971-7.
- (130) Afzelius P, Zedeler K, Sommer H, Mouridsen HT, Blichert-Toft M. Patient's and doctor's delay in primary breast cancer. Prognostic implications. *Acta Oncol* 1994;33(4):345-51.
- (131) Andreasen AH, Andersen KW, Madsen M, Mouridsen H, Olesen KP, Lyng E. Regional trends in breast cancer incidence and mortality in Denmark prior to mammographic screening. *Br J Cancer* 1994 July;70(1):133-7.
- (132) Andreasen AH, Andersen KW, Madsen M, Mouridsen HT, Olesen KP, Lyng E. [Mammographic examinations in Denmark, 1990-1991]. *Ugeskr Laeger* 1994 October 31;156(44):6517-20.
- (133) Andreasen AH, Mouridsen HT, Andersen KW, Lyng E, Madsen M, Olesen KP. [Improved prognosis of breast cancer]. *Ugeskr Laeger* 1994 October 31;156(44):6512-7.
- (134) Andreasen AH, Mouridsen HT, Andersen KW, Lyng E, Madsen M, Olesen KP. Equity and improvement in outcome of breast cancer in Denmark. *Stud Health Technol Inform* 1994;14:27-38.
- (135) Balslev I, Christensen IJ, Rasmussen BB, Larsen JK, Lykkesfeldt AE, Thorpe SM et al. Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer. *Int J Cancer* 1994 January 2;56(1):16-25.
- (136) Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT. The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). *Breast Cancer Res Treat* 1994;32(3):281-90.
- (137) Haerslev T, Jacobsen GK. Proliferating cell nuclear antigen in breast carcinomas. An immunohistochemical study with correlation to histopathological features and prognostic factors. *Virchows Arch* 1994;424(1):39-46.

- (138) Haerslev T, Jacobsen GK. c-erbB-2 oncoprotein is not an independent prognostic parameter in primary breast carcinoma. An immunohistochemical study. *APMIS* 1994 August;102(8):612-22.
- (139) Haerslev T, Jacobsen K, Nedergaard L, Zedeler K. Immunohistochemical detection of metallothionein in primary breast carcinomas and their axillary lymph node metastases. *Pathol Res Pract* 1994 August;190(7):675-81.
- (140) Jakobsen P, Sorensen B, Bastholt L, Mirza MR, Gjedde SB, Mouridsen HT et al. The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients. *Cancer Chemother Pharmacol* 1994;35(1):45-52.
- (141) Kristensen B, Ejlersen B, Dalgaard P, Larsen L, Holmegaard SN, Transbol I et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. *J Clin Oncol* 1994 May;12(5):992-7.
- (142) Kroman N, Hojgaard A, Andersen KW, Graversen HP, Afzelius P, Lokdam A et al. Timing of surgery in relation to menstrual cycle does not predict the prognosis in primary breast cancer. Danish Breast Cancer Cooperative Group. *Eur J Surg Oncol* 1994 August;20(4):430-5.
- (143) Ladekarl M SF. The prognostic value of quantitative histopathology in breast cancer: results of retrospective studies. *Acta Stereol* 1994;13:69-74.
- (144) Nielsen JC, Andersen E, Zedeler K. [Breast cancer in the county of Viborg during 1983-1989. A quality control study]. *Ugeskr Laeger* 1994 May 2;156(18):2737-41.
- (145) Pedersen L, Holck S, Schiodt T, Zedeler K, Mouridsen HT. Medullary carcinoma of the breast, prognostic importance of characteristic histopathological features evaluated in a multivariate Cox analysis. *Eur J Cancer* 1994;30A(12):1792-7.
- (146) Pedersen L, Larsen JK, Christensen IJ, Lykkesfeldt A, Holck S, Schiodt T. DNA ploidy and S-phase fraction in medullary carcinoma of the breast--a flow cytometric analysis using archival material. *Breast Cancer Res Treat* 1994;29(3):297-306.
- (147) Sorensen B, Bastholt L, Mirza MR, Gjedde SB, Jakobsen P, Mouridsen HT et al. The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer. *Cancer Chemother Pharmacol* 1994;34(5):439-43.
- (148) Zedeler K, Keiding N, Kamby C. [The significance of prognostic factors on the occurrence of metastases from breast cancer to various localizations]. *Ugeskr Laeger* 1994 January 3;156(1):42-7.
- (149) Afzelius P, Zedeler K, Sommer H, Mouridsen HT, Blichert-Toft M. [Significance for prognosis of delayed diagnosis and treatment of breast cancer]. *Ugeskr Laeger* 1995 June 26;157(26):3762-5.
- (150) Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. *N Engl J Med* 1995 November 30;333(22):1444-55.
- (151) Gelber RD, Cole BF, Goldhirsch A, Bonadonna G, Howell A, McArdle CS et al. Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. *Cancer J Sci Am* 1995 July;1(2):114-21.
- (152) Grabau DA. A population-based analysis of breast cancers in a region at Funen, 1980-1990. Relevance of histological, biological, and clinical prognostic factors. Odense Universitet; 1995.

- (153) Groenvold M, Bjorner JB, Klee MC, Kreiner S. Test for item bias in a quality of life questionnaire. *J Clin Epidemiol* 1995 June;48(6):805-16.
- (154) Haerslev, T. and Jacobsen GK. Proliferating cell nuclear antigen (PCNA) and c-erbB-2 oncoprotein in breast carcinoma with correlations to histopathological parameters and prognosis. 1995. Report No.: 2.
- (155) Haerslev T, Jacobsen GK. An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. *Hum Pathol* 1995 March;26(3):295-301.
- (156) Haerslev T, Jacobsen GK, Zedeler K. The prognostic significance of immunohistochemically detectable metallothionein in primary breast carcinomas. *APMIS* 1995 April;103(4):279-85.
- (157) Husted H, Lauridsen MC, Torsleff K, Erichsen C. [Late symptoms among patients surgically treated for breast cancer. A questionnaire in the county of Southern Jutland]. *Ugeskr Laeger* 1995 December 4;157(49):6868-72.
- (158) Hærsløv T. The prognostic significance of proliferating cell nuclear antigen (PCNA) and c-erbB-2-oncoprotein in primary breast carcinomas. An immunohistochemical study. (Ph.D. Thesis) Københavns Universitet.; 1995.
- (159) Kroman NT, Hojgaard AD, Andersen KW, Graversen HP, Afzelius P, Lokdam AV et al. [Menstrual cycle and surgery of breast cancer. Point of time for the surgery of primary breast cancer in connection with menstrual cycle is without prognostic significance]. *Ugeskr Laeger* 1995 October 23;157(43):5989-93.
- (160) Ladekarl M. Quantitative histopathology in ductal carcinoma of the breast. Prognostic value of mean nuclear size and mitotic counts. *Cancer* 1995;75(8):2114-22.
- (161) Pedersen L, Zedeler K, Holck S, Schiødt T, Mouridsen HT. Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer. *Eur J Cancer* 1995 December;31A(13-14):2289-95.
- (162) Romain S, Christensen IJ, Chinot O, Balslev I, Rose C, Martin PM et al. Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer. *Int J Cancer* 1995 March 29;61(1):7-12.
- (163) Bastholt L, Dalmark M, Gjedde SB, Pfeiffer P, Pedersen D, Sandberg E et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. *J Clin Oncol* 1996 April;14(4):1146-55.
- (164) Blichert-Toft M, Mouridsen H, Andersen KW. Clinical trials. *Semin Surg Oncol* 1996 January;12(1):32-8.
- (165) Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. *Lancet* 1996 April 20;347(9008):1066-71.
- (166) Grønvold M. Validation of a quality of life questionnaire for breast cancer patients. Københavns Universitet.; 1996.
- (167) Haerslev T, Jacobsen GK, Zedeler K. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. *Breast Cancer Res Treat* 1996;37(2):101-13.

- (168) Hirsch FR, Mouridsen HT, Hansen OP, Jorgensen T, Blichert-Toft M, Rank FE et al. [Treatment of primary breast cancer. Consequences of mammographic screening in the municipality of Copenhagen]. *Ugeskr Laeger* 1996 February 26;158(9):1218-21.
- (169) Kristensen B, Ejlertsen B, Mouridsen HT, Andersen KW, Lauritzen JB. Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. *Breast Cancer Res Treat* 1996;39(3):321-6.
- (170) Pfeiffer P, Rose C, Ejlertsen B, Andersson M, Pedersen D, Mouridsen HT. Concurrent tamoxifen (TAM) + cyclophosphamide, epirubicin, and fluorouracil (CEF) versus TAM + delayed CEF after six months of endocrine therapy in metastatic breast cancer--a randomized trial from the Danish Breast Cancer Cooperative Group (DBCG). *Acta Oncol* 1996;35 Suppl 5:57.
- (171) Groenvold M, Klee MC, Sprangers MA, Aaronson NK. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. *J Clin Epidemiol* 1997 April;50(4):441-50.
- (172) Grondahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M et al. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. *Clin Cancer Res* 1997 February;3(2):233-9.
- (173) Hansen PS, Andersen E, Andersen KW, Mouridsen HT. Quality control of end results in a Danish adjuvant breast cancer multi-center study. *Acta Oncol* 1997;36(7):711-4.
- (174) Kroman N, Wohlfahrt J, Andersen KW, Mouridsen HT, Westergaard T, Melbye M. Time since childbirth and prognosis in primary breast cancer: population based study. *BMJ* 1997 October 4;315(7112):851-5.
- (175) Kroman N, Jensen MB, Melbye M, Wohlfahrt J, Mouridsen HT. Should women be advised against pregnancy after breast-cancer treatment? *Lancet* 1997 August 2;350(9074):319-22.
- (176) Morris AD, Morris RD, Wilson JF, White J, Steinberg S, Okunieff P et al. Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. *Cancer J Sci Am* 1997 January;3(1):6-12.
- (177) Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. *N Engl J Med* 1997 October 2;337(14):949-55.
- (178) Pedersen L. Medullary Carcinoma of the Breast. *APMIS* 1997;105:5-31.
- (179) Blichert-Toft M. The axilla: to clear or not to clear? That is the question! *Recent Results Cancer Res* 1998;152:149-60.
- (180) Cold S. Kropsbygning og brystkræft. Odense Universitet.; 1998.
- (181) Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. *Lancet* 1998 September 19;352(9132):930-42.
- (182) Grabau DA, Jensen MB, Blichert-Toft M, Andersen JA, Dyreborg U, Carstensen B et al. The importance of surgery and accurate axillary staging for survival in breast cancer. *Eur J Surg Oncol* 1998 December;24(6):499-507.
- (183) Jensen VED. Prognostiske tumorparametre i mamma cancer. Aarhus Universitet.; 1998.

- (184) Knoop A. Prognostic and predictive factors in primary high risk postmenopausal breast cancer. Odense Universitet.; 1998.
- (185) Kroman N, Wohlfahrt J, Andersen KW, Mouridsen HT, Westergaard T, Melbye M. Parity, age at first childbirth and the prognosis of primary breast cancer. *Br J Cancer* 1998 December;78(11):1529-33.
- (186) Ladekarl M. Objective malignancy grading: A review emphasizing unbiased stereology applied to breast tumors. *APMIS* 1998;(106):5-34.
- (187) Lynge E. Mammography screening for breast cancer in Copenhagen April 1991-March 1997. Mammography Screening Evaluation Group. *APMIS Suppl* 1998;83:1-44.
- (188) Norredam M, Groenvold M, Petersen JH, Krasnik A. Effect of social class on tumour size at diagnosis and surgical treatment in Danish women with breast cancer. *Soc Sci Med* 1998 December;47(11):1659-63.
- (189) Voogd AC. Breast-conserving treatment of operable mammary cancer: evaluation of patient selection and treatment outcome. Universiteit van Amsterdam.; 1998.
- (190) Andersson M, Madsen EL, Overgaard M, Rose C, Dombernowsky P, Mouridsen HT. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. *Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer* 1999 January;35(1):39-46.
- (191) Andersson M, Kamby C, Jensen MB, Mouridsen H, Ejlertsen B, Dombernowsky P et al. Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial. *Eur J Cancer* 1999 November;35(12):1659-66.
- (192) Groenvold M, Fayers PM, Sprangers MA, Bjorner JB, Klee MC, Aaronson NK et al. Anxiety and depression in breast cancer patients at low risk of recurrence compared with the general population: a valid comparison? *J Clin Epidemiol* 1999 June;52(6):523-30.
- (193) Hojris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. *Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet* 1999 October 23;354(9188):1425-30.
- (194) Mortensen K, Holck S, Christensen IJ, Skouv J, Hougaard DM, Blom J et al. Endothelial cell nitric oxide synthase in peritumoral microvessels is a favorable prognostic indicator in premenopausal breast cancer patients. *Clin Cancer Res* 1999 May;5(5):1093-7.
- (195) Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. *Lancet* 1999 May 15;353(9165):1641-8.
- (196) van Tienhoven G, Voogd AC, Peterse JL, Nielsen M, Andersen KW, Mignolet F et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). *EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer* 1999 January;35(1):32-8.
- (197) Wohlfahrt J, Andersen PK, Mouridsen HT, Adami HO, Melbye M. Reproductive history and stage of breast cancer. *Am J Epidemiol* 1999 December 15;150(12):1325-30.

- (198) Wohlfahrt J, Mouridsen H, Andersen PK, Melbye M. Reproductive risk factors for breast cancer by receptor status, histology, laterality and location. *Int J Cancer* 1999 March 31;81(1):49-55.
- (199) Wohlfahrt J, Melbye M. Maternal risk of breast cancer and birth characteristics of offspring by time since birth. *Epidemiology* 1999 July;10(4):441-4.
- (200) Axelsson CK, Rank F, Blichert-Toft M, Mouridsen HT, Jensen MB. Impact of axillary dissection on staging and regional control in breast tumors  $\leq 10$  mm--the DBCG experience. The Danish Breast Cancer Cooperative Group (DBCG), Rigshisoutalet, Copenhagen, Denmark. *Acta Oncol* 2000;39(3):283-9.
- (201) Blichert-Toft M. Axillary surgery in breast cancer management--background, incidence and extent of nodal spread, extent of surgery and accurate axillary staging, surgical procedures. *Acta Oncol* 2000;39(3):269-75.
- (202) Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. *Lancet* 2000 May 20;355(9217):1757-70.
- (203) Hojris I, Andersen J, Overgaard M, Overgaard J. Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. *Acta Oncol* 2000;39(3):355-72.
- (204) Johansen J, Overgaard J, Blichert-Toft M, Overgaard M. Treatment of morbidity associated with the management of the axilla in breast-conserving therapy. *Acta Oncol* 2000;39(3):349-54.
- (205) Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: population based study. *BMJ* 2000 February 19;320(7233):474-8.
- (206) Kroman N, Thorpe SM, Wohlfahrt J, Andersen KW, Mouridsen HT. Variations in prognostic factors in primary breast cancer throughout the menstrual cycle. *Eur J Surg Oncol* 2000 February;26(1):11-6.
- (207) Kroman NT, Jensen MB, Wohlfahrt J, Mouridsen H, Andersen PK, Melbye M. [Should all younger patients with breast cancer be offered adjuvant cytotoxic chemotherapy?]. *Ugeskr Laeger* 2000 May 29;162(22):3184-8.
- (208) Lauridsen MC, Torsleff KR, Husted H, Erichsen C. Physiotherapy treatment of late symptoms following surgical treatment of breast cancer. *Breast* 2000 February;9(1):45-51.
- (209) Ottesen GL, Graversen HP, Blichert-Toft M, Christensen IJ, Andersen JA. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. *Breast Cancer Res Treat* 2000 August;62(3):197-210.
- (210) Overgaard J, Yilmaz M, Guldborg P, Hansen LL, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. *Acta Oncol* 2000;39(3):327-33.
- (211) Overgaard M. Evaluation of radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. *Rays* 2000 July;25(3):325-30.
- (212) Rostgaard K, Holst H, Mouridsen HT, Lyng E. Do clinical databases render population-based cancer registers obsolete? The example of breast cancer in Denmark. *Cancer Causes Control* 2000 August;11(7):669-74.

- (213) Seegenschmiedt MH. [Long-term cardiac sequelae of adjuvant radiotherapy after mastectomy? Analysis of Danish DBCG-82b/82c trials]. *Strahlenther Onkol* 2000 April;176(4):197-8.
- (214) Wohlfahrt J, Melbye M. Gender of offspring and long-term maternal breast cancer risk. *Br J Cancer* 2000 March;82(5):1070-2.
- (215) Bergthorsson JT, Ejlersen B, Olsen JH, Borg A, Nielsen KV, Barkardottir RB et al. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. *J Med Genet* 2001 June;38(6):361-8.
- (216) Kroman N. Prognostic influence of age and reproductive factors in premenopausal breast cancer patients. University of Copenhagen; 2001.
- (217) Rostgaard K, Mouridsen HT, Vaeth M, Holst H, Olesen KP, Lyng E. A modified Nottingham prognostic index for breast cancer patients diagnosed in Denmark 1978-1994. *Acta Oncol* 2001;40(7):838-43.
- (218) Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. *J Clin Oncol* 2001 March 15;19(6):1688-97.
- (219) Blichert-Toft M, Kroman N. The specialist breast unit and breast surgery as a specialty. *Scand J Surg* 2002;91(3):227-31.
- (220) Blichert-Toft M, Ejlersen B, Mouridsen H, Overgaard M. [Breast cancer]. *Ugeskr Laeger* 2002 June 3;164(23):3023-6.
- (221) Jensen AR, Overgaard J, Storm HH. Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark. *Eur J Cancer Prev* 2002 August;11(4):359-64.
- (222) Johansen J, Overgaard J, Rose C, Engelholm SA, Gadeberg CC, Kjaer M et al. Cosmetic outcome and breast morbidity in breast-conserving treatment--results from the Danish DBCG-82TM national randomized trial in breast cancer. *Acta Oncol* 2002;41(4):369-80.
- (223) Kroman N, Melbye M, Mouridsen HT. Prognostic influence of age at diagnosis in premenopausal breast cancer patients. *Scand J Surg* 2002;91(3):305-8.
- (224) Offersen BV, Sorensen FB, Yilmaz M, Knoop A, Overgaard J. Chalkley estimates of angiogenesis in early breast cancer--relevance to prognosis. *Acta Oncol* 2002;41(7-8):695-703.
- (225) Tange UB, Hirsch FR, Jensen MB, Olsen AH, Blichert-Toft M, Rank FE et al. [Mammography screening in the county of Copenhagen. Results of the first three screening rounds]. *Ugeskr Laeger* 2002 February 18;164(8):1048-52.
- (226) Tange UB, Jensen MB, Vejborg IM, Rank FE, Blichert-Toft M, Mouridsen HT et al. Clinical impact of introduction of mammography screening in a non-screening country with special reference to the Copenhagen service mammography screening programme. *Scand J Surg* 2002;91(3):293-303.
- (227) Tange UB, Hirsch FR, Jensen MB, Olsen AH, Blichert-Toft M, Rank FE et al. [Mammographic screening in the county of Copenhagen. Clinical consequences of the first three screening rounds]. *Ugeskr Laeger* 2002 February 18;164(8):1036-40.
- (228) Vejborg I, Olsen AH, Jensen MB, Rank F, Tange UB, Lyng E. Early outcome of mammography screening in Copenhagen 1991-99. *J Med Screen* 2002;9(3):115-9.

- (229) Celis JE, Gromov P, Gromova I, Moreira JM, Cabezon T, Ambartsumian N et al. Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. *Mol Cell Proteomics* 2003 June;2(6):369-77.
- (230) Ejllertsen B, Hojris I, Hansen S, Moholt K, Kristensen B, Mouridsen HT et al. Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group. *Breast* 2003 February;12(1):42-50.
- (231) Hjerl K, Andersen EW, Keiding N, Mouridsen HT, Mortensen PB, Jorgensen T. Depression as a prognostic factor for breast cancer mortality. *Psychosomatics* 2003 January;44(1):24-30.
- (232) Holmich LR, Mellekjaer L, Gunnarsdottir KA, Tange UB, Krag C, Moller S et al. Stage of breast cancer at diagnosis among women with cosmetic breast implants. *Br J Cancer* 2003 March 24;88(6):832-8.
- (233) Jensen AR, Storm HH, Moller S, Overgaard J. Validity and representativity in the Danish Breast Cancer Cooperative Group--a study on protocol allocation and data validity from one county to a multi-centre database. *Acta Oncol* 2003;42(3):179-85.
- (234) Jensen AR, Garne JP, Storm HH, Ewertz M, Cold S, Alvegaard T et al. Stage and survival in breast cancer patients in screened and non-screened Danish and Swedish populations. *Acta Oncol* 2003;42(7):701-9.
- (235) Jensena AR, Ewertz M, Cold S, Storm HH, Overgaard J. Time trends and regional differences in registration, stage distribution, surgical management and survival of breast cancer in Denmark. *Eur J Cancer* 2003 August;39(12):1783-93.
- (236) Kroman N, Mouridsen HT. Prognostic influence of pregnancy before, around, and after diagnosis of breast cancer. *Breast* 2003 December;12(6):516-21.
- (237) Kroman N, Wohlfahrt J, Mouridsen HT, Melbye M. Influence of tumor location on breast cancer prognosis. *Int J Cancer* 2003 July 1;105(4):542-5.
- (238) Offersen BV, Sorensen FB, Knoop A, Overgaard J. The prognostic relevance of estimates of proliferative activity in early breast cancer. *Histopathology* 2003 December;43(6):573-82.
- (239) Ottesen GL. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. *APMIS Suppl* 2003;(108):1-67.
- (240) Vejborg I FEB-TM. *Brystkræft kan opdages i tide*. Scandinavian Health News. København: FADL's Forlag; 2003.
- (241) Christensen LH, Engholm G, Ceberg J, Hein S, Perfekt R, Tange UB et al. Can the survival difference between breast cancer patients in Denmark and Sweden 1989 and 1994 be explained by patho-anatomical variables?--a population-based study. *Eur J Cancer* 2004 May;40(8):1233-43.
- (242) Ejllertsen B, Mouridsen HT, Langkjer ST, Andersen J, Sjostrom J, Kjaer M. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). *J Clin Oncol* 2004 June 15;22(12):2313-20.
- (243) Kroman N, Holtveg H, Wohlfahrt J, Jensen MB, Mouridsen HT, Blichert-Toft M et al. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. *Cancer* 2004 February 15;100(4):688-93.
- (244) Mouridsen HT, Brunner N. Clinical infrastructures to support proteomic studies of tissue and fluids in breast cancer. *Mol Cell Proteomics* 2004 April;3(4):302-10.



- (245) Olsen A, Knudsen KE, Thomsen BL, Loft S, Stripp C, Overvad K et al. Plasma enterolactone and breast cancer incidence by estrogen receptor status. *Cancer Epidemiol Biomarkers Prev* 2004 December;13(12):2084-9.
- (246) Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlersen B et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. *Acta Oncol* 2004;43(1):35-42.
- (247) Pedersen L, Gunnarsdottir KA, Rasmussen BB, Moeller S, Lanng C. The prognostic influence of multifocality in breast cancer patients. *Breast* 2004 June;13(3):188-93.
- (248) Tjonneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M et al. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. *Cancer* 2004 June 1;100(11):2328-37.
- (249) Wohlfahrt J, Rank F, Kroman N, Melbye M. A comparison of reproductive risk factors for CIS lesions and invasive breast cancer. *Int J Cancer* 2004 February 20;108(5):750-3.
- (250) Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005 December 17;366(9503):2087-106.
- (251) Cold S, Durning M, Ewertz M, Knoop A, Moller S. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). *Br J Cancer* 2005 September 19;93(6):627-32.
- (252) Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. *Lancet Oncol* 2005 August;6(8):557-65.
- (253) Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. *J Clin Oncol* 2005 October 20;23(30):7483-90.
- (254) Nielsen HM, Overgaard J, Grau C, Christensen JJ, Overgaard M. Audit of the radiotherapy in the DBCG 82 b&c trials--a validation study of the 1,538 patients randomised to postmastectomy radiotherapy. *Radiother Oncol* 2005 September;76(3):285-92.
- (255) Nielsen TG, Olsen A, Christensen J, Overvad K, Tjonneland A. Dietary carbohydrate intake is not associated with the breast cancer incidence rate ratio in postmenopausal Danish women. *J Nutr* 2005 January;135(1):124-8.
- (256) Olsen AH, Njor SH, Vejborg I, Schwartz W, Dalgaard P, Jensen MB et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. *BMJ* 2005 January 29;330(7485):220.
- (257) Wohlfahrt J. *Pregnancy and Breast Cancer*. University of Copenhagen; 2005.
- (258) Dalton SO, Durning M, Ross L, Carlsen K, Mortensen PB, Lynch J et al. The relation between socioeconomic and demographic factors and tumour stage in women diagnosed with breast cancer in Denmark, 1983-1999. *Br J Cancer* 2006 September 4;95(5):653-9.

- (259) Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S et al. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. *J Clin Oncol* 2006 November 1;24(31):4956-62.
- (260) Groenvold M, Fayers PM, Petersen MA, Mouridsen HT. Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial. *Breast Cancer Res Treat* 2006 August;98(3):275-84.
- (261) Kyndi M, Alsner J, Hansen LL, Sorensen FB, Overgaard J. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. *Acta Oncol* 2006;45(5):602-9.
- (262) Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. *J Clin Oncol* 2006 May 20;24(15):2268-75.
- (263) Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Loco-regional recurrence after mastectomy in high-risk breast cancer--risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. *Radiother Oncol* 2006 May;79(2):147-55.
- (264) Rostgaard K, Vaeth M, Rootzén H, Mouridsen H, Olesen KP, Lyng E. Do changes in lymph node status distribution explain trends in survival of breast cancer patients in Denmark? *Eur J Cancer Prev.* 2006 Oct;15(5):398-404.